Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin(Hebron University), Juan Cueva(Instituto de Investigación Sanitaria de Santiago), Hanna Dahlstrand(Uppsala University), Radoslav Chekerov(Charité - Universitätsmedizin Berlin), Anne Gry Bentzen, Line Bjørge(Haukeland University Hospital), Coriolan Lebreton(Institut Bergonié), Véronique D’Hondt(Virginia Cancer Institute), Alexandra Léary(Institut Gustave Roussy), Ana Godoy-Ortíz(Kurume University Hospital), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Maria Bjurberg, Bertrand Billemont(Délégation Paris 5), Dominique Berton(Institut de Cancérologie de l'Ouest), Sophie Abadie‐Lacourtoisie, Luís Manso(Research Institute Hospital 12 de Octubre), Florence Joly(Centre François Baclesse), Maria-Pilar Barretina-Ginesta, Antoine Angelergues(Groupe Hospitalier Diaconesses Croix Saint-Simon), Cláudia Casanova, Linda Duska(University of Virginia Medical Center), Marco Johannes Battista(Johannes Gutenberg University Mainz), Lorena Fariñas-Madrid(Vall d'Hebron Hospital Universitari), Jesús Alarcón(Hospital Universitario Son Espases), Domenica Lorusso(Agostino Gemelli University Polyclinic), Elena Ioana Braicu, Munetaka Takekuma(Shizuoka Cancer Center), Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Kristina Lindemann(Norwegian Cancer Society), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Mayu Yunokawa(Japanese Foundation For Cancer Research), Nerea Anzizar, Daiseuke Aoki, Nicoletta Colombo(University of Milano-Bicocca), Destin Black, Philippe Follana(Nordic Society of Gynecologic Oncology), Jerónimo Martínez-García(Institute of Cancer Research), Annick Chevalier, Alessandra Bologna(Azienda Sanitaria Unità Locale di Reggio Emilia), Charlotte Béllier, Laurence Gladieff(Institut Claudius Regaud)
Cited by 225
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k